Skip to main content

Advertisement

Table 1 Literature review: randomized studies with different hypofractionation schedules in breast cancer patients, LR = local recurrence, CTx = chemotherapy, RT ln = periclavicular radiotherapy of lymph nodes, *not randomized

From: Hypofractionated radiotherapy for breast cancer acceleration of the START A treatment regime: intermediate tolerance and efficacy

Study Pat. FU (yrs) Prescription dose in Gy (weeks) LR Induration Teleangiectasia Breast edema Excellent or good cosmetic outcome CTX RT ln Boost
Whelan “Ontario Trial” (2010) [7] 1234 10 25×2 = 50 6,7% 10.4%    71.3% 11% 0% 0%
   16×2,66 = 42,5 (3) 6,2% 11.9%    69.8%    
Yarnold (2005) 1410 10 25×2 = 50 12,1% 28.6% 13.8% 12.6%   14% 21% 75%
Owen (2006) [9]
“START Pilot study”
   13×3,3 = 42,9 (5)   40.8% 14.3% 20.3%     (7×2 = 14 Gy)
   13×3,0 = 39 (5) 9,6% 20.4% 8.6% 10.8%     
     14,8%        
START A (2013) [8] 2236 10 25×2 = 50 6.7% 27.1% 7.2% 13.5%   35% 14% 61%
   13×3,2 = 41,6 (5) 5.6% 28.2% 7.1% 11.8%     (5×2 = 10 Gy)
   13×3,0 = 39 (5) 8.1% 21.6% 3.0% 7.3%     
START B (2013) [8] 2215 10 25×2 = 50 5.2% 17.4% 5.8% 9.0%   22% 7% 43%
   15×2,67 = 40 (3) 3.8% 14.3% 4.2% 5.1%     (5×2 = 10 Gy)
Kim (2013)* [12] 276 5 13×3 = 39 (3.2) 1.4% 3% (1y) 2% (2y)   20.4% (1y) 3% (2y) 83% 74% 0% 100% (3×3 = 9 Gy)
Present study* 98 3 13×3.2 = 41.6
(3.2)
0% 15% (1y) 7% (2y) 6% (1y) 22% (2y) 11% (1y) 0% (2y) 99% (1y) 97% (2y) 24% 3% 99% (3×3 = 9 Gy)